Otsuka Pharmaceutical and Proteus Digital Health re-submitted an FDA application for their chip-in-a-pill, which combines antipsychotic Abilify with an ingestible sensor made by Proteus. The FDA is ...
Forbes contributors publish independent expert analyses and insights. Robert Glatter is a New York-based physician covering public health. When a healthcare provider writes a prescription for a ...
REDWOOD CITY, Calif. – July 30, 2012 – Proteus Digital Health, Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared its ingestible sensor for marketing as a medical device ...
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Proteus Digital Health, Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared its ingestible sensor for marketing as a medical device ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback